Policy changes related to telemedicine that were quickly implemented during the novel coronavirus pandemic (COVID-19) have created opportunities for technology-based clinical evaluation, which serves to protect patients and providers alike, while conserving personal protective equipment (PPE).

Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.

Spasticity — a consequence of stroke and other disorders of the central nervous system — may be underdiagnosed and undertreated in nursing home residents.

Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.

Vanderbilt researchers have identified haplotypes, ancestral fragments of DNA, that are associated with hereditary prostate cancer (HPC) in a first-of-its-kind genomic study made possible by the study of prostate cancer patients with family histories of the disease.

New insights on influenza genome packaging could guide strategies for interfering with the virus’s life cycle and ability to cause infection.

Variation in the levels of hormones called natriuretic peptides may contribute to racial differences in susceptibility to diabetes, suggesting that this hormone system may be a target for reducing risk of the disease.